Anti-EGFR CAR-transduced T-cell therapy - Cellular Biomedicine Group

Drug Profile

Anti-EGFR CAR-transduced T-cell therapy - Cellular Biomedicine Group

Alternative Names: CART-EGFR; CART-HER1; CBM-EGFR.1; CBM-EGFR1; Chimeric antigen receptor-modified T cells immunotherapy - Cellular Biomedicine Group; Chimeric EGFR antigen receptor T cell therapy - Cellular Biomedicine Group; Chimeric epidermal growth factor receptor T cell therapy - Cellular Biomedicine Group; Chimeric-EGFR-antigen-receptor-modified-T-cells

Latest Information Update: 21 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Chinese PLA General Hospital
  • Developer Cellular Biomedicine Group; Chinese PLA General Hospital
  • Class Cancer vaccines; CAR-T cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 28 Sep 2015 Interim efficacy and adverse events data from a phase I/II trial in Solid tumours released by Cellular Biomedicine Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top